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Abstract
Thiopurine methyltransferase (TPMT) is an important enzyme in the metabolism of 6-mercaptoptirine (6MP), which is 
used in the treat men t of acute lymphoblastic leukemia (ALL). TPMT catalyzes the formation of methylthioi nosine 
monophosphate (MetlMP), which is cytotoxic for cultured cell lines, and it plays a role in detoxification of 6MP, Population 
studies show a genetic polymorphism for TPMT with both high and low activity alleles. About 1 of 300 subjects is 
homozygous for the low activity. The function TPMT plays in detoxification or therapeutic efficacy of 6MP in vivo is not 
clear. In this article the genetic polymorphism of TPMT is reviewed and the contribution of TPMT to the cytotoxic action, or 
detoxification, of 6MP in children with ALL is discussed. Induction of TPMT activity has been described during the 
treatment for ALL. We performed a pilot study on the influence of higlvdose 6MP infusions (1300 m g /m 2 in 24 h) on TPMT 
activity of peripheral blood mononuclear cells (pMNC) of eleven patients with ALL. The TPMT activities were in, or, above 
the normal range. There was no statistically significant difference between the TPMT activities before and after the 6MP 
infusions. MetlMP levels in pMNC increased during successive courses. This might be explained by TPMT induction, but 
other explanations are plausible as well. Twenty five percent of the TPMT assays failed, because less than the necessary 
5*i0f’ pMNC could be isolated from the blood of leukopenic patients. Red blood cells can not be used for TPMT 
measurements, since transfusions are frequently required during the treatment with 6MP infusions. Therefore, the influence 
of high-dose 6MP infusions on TPMT activity can only be investigated further when a TPMT assay which requires less 
pMNC has been developed.
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1. Involvement of thiopurine methyltransferase in 
the metabolism of 6-mercaptopurine
Thiopurine methyltransferase (TPMT) is involved 
in the méthylation reactions of 6-mercaptopurine 
(6MP). Since 1953, 6MP has been administered in 
the treatment of childhood acute lymphoblastic 
leukemia (ALL) and is converted by several metabol­
ic steps (Fig. 1). 6MP is eatabolized by xanthine
Corresponding author.
oxidase into inactive thioxanthine and thiouric acid
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which are excreted by the kidneys [1-4]. In the 
anabolic pathway, 6MP is first converted into 
thioinosine monophosphate by hypoxanthine guanine 
phosphoribosy I transferase (HGPRT). To have a 
cytotoxic effect this compound is either converted 
into a thiogiianine nucleotide or it is methylated by 
TPMT into methylthioinosine monophosphate 
(MetlMP), Incorporation of thiogiianine nucleotides 
(TGN) into DNA and RNA and inhibition of the de 
novo synthesis of the purine by MetlMP both result
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Fig. L Metabolism of ft-mcrcaptopurinc. 6 MP(R), 6 -mereap- 
topurine-(riboside); ()McMP(R), 6 -mcthylmereaptopurme- 
(riboside); (Me)tlMP, 6 -<uielhy 1 )thioinosi ne monophosphate; 
tGMP, 6 -thioguanosine monophosphate; PDNS, de novo synthesis 
of the purine.(l) thiopurine methyltransfcrase; (2 ) hypoxanthine 
guanine phosphoribosyltrans(erase; (3) purine nucleoside phos- 
phorylase; (4) purine 5'-nueleotidase; (5) adenosine kinase; (6 ) 
inosine monophosphute dehydrogenase; (7) guanosine monophos­
phate synthetase; (8 ) guanosine monophosphate reductase; (9) 
xanthine oxidase.
in cytotoxicity in vitro [5-7]. The importance of 
each cytotoxic pathway in vivo is discussed in 
scction 3. Apart from a decrease in the synthesis of 
DNA and RNA [5], inhibition of the de novo 
synthesis of the purine can also lead to a decrease of 
intracellular S-Adenosyl-L-methionine [8] and of 
DNA methylation [9] in vitro, S-Adenosyl-L- 
methionine is the methyl donor for thiopurine meth­
ylation reactions [10] and for other methylation 
reactions» e.g. proteins, phospholipids and nucleic 
acids [11]. The effects of 6MP on S-adenosyl-L- 
methionine [8] in lymphoblasts may account for an 
additional mechanism of 6MP cytotoxicity.
6-Mereaptopurine riboside is converted into 6-
methylmercaptopurine riboside (MeMPR) t 
which can be phosphorylated intraceliul 
MetIMP by adenosine kinase [12,13] and \ 
not be broken down by purine nucleoside ] 
ylase [14]. The methylation by TPMT of 
6-methylmercaptopurine (MeMP), which 
cytotoxic action, results in detoxification oi
[3].
In conclusion, TPMT is an important e 
the metabolic pathways of 6MP. It eata 
formation of MetIMP, which is an inhibitor 
novo synthesis of the purine in vitro, and 
role in detoxification of the drug.
2. Genetic polymorphism of TPMT
In view of its role in thiopurine meta 
became important to study the genetic back 
the TPMT activity. These studies were lac 
the development of a quantitative assay i 
activity in red blood cell (RBC) lysates 11 
assay the transfer of UC from S-a 
methionine to 6MP is measured.
It became apparent that a marked vi
TPMT activity exists between individual 
The frequency distribution of TPMT ael 
population of white subjects is Irimodal. 
the subjects displayed high activity, 1 
intermediate activity, while the lysates oi 
not contain detectable TPMT activity, 
model for such a distribution is that a sing'
locus governs TPMT activity and that the 
alleles for the locus [171. One allele corr
the high activity form (TPMTU) and 
(TPMTl) to the low activity form. Th 
diploid and both copies are expressed, 
that are homozygous for TPMT] 1 display I 
ty, heterozygotes have intermediate ac 
TPMT1, homozygotes have an activity thi 
the detection level of the assay. The vali< 
model was suggested by the distribution < 
with Hardy-Weinberg statistics for inht 
Mendelian laws. The frequency of TPM 
(0.06 for TPMT1) in the group of whi 
studied. The model was strongly support 
grees with regard to TPMT activity whicl
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in agreement with Mendelian rules. Further studies 
and sophisticated statistical analyses led to the 
conclusion that TPMT activity is governed by a 
single locus, although additional circumstances may 
influence TPMT activity [18,19].
Individual levels of RBC-TPMT activity correlate 
with the levels of TPMT activity found in other 
tissues, including liver, kidney, lymphocytes, 
platelets and lymphoblasts [20-23], Apparently, the 
same genetic locus controls TPMT activity in these 
tissues. TPMT activity has further been detected in 
all other tissues examined: i.e., brain, lung, intestine 
and placenta [24]. The liver and kidney had the 
highest levels of TPMT activity [24].
Age does not have an effect on TPMT activity and 
high levels of TPMT activity have been found in 
fetal tissues [24]. It has been reported that tissues 
derived from males have approximately 10% higher 
levels of TPMT activity than those from females 
[19,23,25], but other studies do not find significant 
sex differences [26-28]. Uneven frequency distribu­
tions of TPMT activity are also found in diverse 
ethnic groups [26,28]. The frequency of TPMTL was 
0.02 in a group of Chinese subjects [28]. Differences 
in the activity levels between ethnic groups may be 
caused by laboratory circumstances [28], However, 
when measured at the same laboratory, the levels of 
TPMT activity in samples from black subjects were 
17% lower than those from white subjects, while 
similar proportions of high and intermediate activity 
were present in both groups [29].
Molecular biological studies were initiated with 
the partial purification of TPMT and production of 
specific antibodies [22]. TPMT is a cytoplasmic 
protein of 35 kDa [30,31]. Titration of the TPMT 
activity with antibodies indicated that variation of the 
TPMT activity between individuals corresponds to 
variation in the amount of TPMT protein [22]*
The TPMT activity from kidney homogenates was 
resolved in two peaks by ion-exchange chromatog­
raphy on DEAE-Sepharose [31]. These two activities 
behaved identically in all further experiments, which 
included kinetic studies, size exclusion chromatog­
raphy, gel electrophoresis and column-chromatog- 
raphy on hydroxylapatite [31,32], The nature of the 
difference in these isoenzymes is not known. Studies 
using individual samples clearly ruled out any link
between genetic polymorphism and the existence of 
the two isoenzymes [31].
Extensive purification of TPMT was achieved 
after UV cross-linking of the protein to its labeled 
co-factor [3H-methyl]S-adenosyl-L-methionine. 
TPMT could thus be monitored by measuring its 
radioactivity instead of its enzyme activity [32].
A cDNA of human TPMT mRNA was cloned 
using peptide sequences of purified protein fragments 
[33,34]. A liver cDNA of 1.8 kb was cloned that has 
an open reading frame of 245 amino acids [34]. The 
identity of this cDNA was confirmed by expression 
of the coding region in COS cells, which resulted in 
an increase of TPMT activity [33]. The derived 
amino acid sequence of TPMT lacks the three 
regions that are commonly found in other S- 
adenosyl-L-methionine binding proteins [33], It will 
be interesting to see whether the methyl donor is a 
co-factor for the physiological function of this 
protein.
The gene structure, including its regulatory, se­
quences has not been resolved yet. Cloning of the 
gene is obstructed - by the presence of a processed 
pseudo-gene on chromosome 18q21 [34]. The pseu­
do-gene originates from a reverse transcription event 
with TPMT mRNA.
The cDNA of one patient with TPMT-deficiency 
was analyzed [35]. Cloned cDNA from this patient 
was mutated in the open reading frame, leading to an 
amino acid substitution of Ala at position 80 to Pro. 
The corresponding cDNA was expressed in yeast 
and, contrary to the wildtype cDNA, the mutant 
protein had no TPMT activity. The pedigree of this 
patient indicates that the point-mutation accounts for 
only one copy of the gene, as the second copy seems 
to be affected by another mutation.
Mutations that affect TPMT activity may leave the 
physiological activity unchanged. Since TPMT is 
present in all tissues examined, from an early stage 
of development, it may represent an important or 
essential household protein. Knock-out and mutation 
experiments in mice should be performed to test 
these ideas.
The preliminary DNA sequence data indicate that 
different mutations are responsible for the TPMTL 
allele. Clearly, an inventory of existing mutations 
that lead to TPMT-deficiency is required.
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3. TPMT and its contribution to the cytotoxic 
action or detoxification of 6MP
The genetic polymorphism of TPMT is not appar­
ent in healthy subjects, but becomes important when 
thiopurine drugs, which are metabolized by this 
enzyme, are administered. Several patients developed 
signs of severe toxicity following 6MP treatment and 
it was demonstrated that they were deficient in 
TPMT activity [36-38]. Apart from its influence on 
6MP toxicity, TPMT activity also appears to play a 
role in the prognosis and survival of childhood ALL, 
reflecting its importance in the therapeutic efficacy of 
6MP. All studies that reveal insight into the efficacy 
of 6MP, and into the relevance of each cytotoxic 
pathway of 6MP in vivo, are performed in RBC 
during 1.5 to 2.5 years of maintenance therapy (MT) 
for childhood ALL, where low daily oral doses of 
6MP (50-100 mg/m2) and weekly doses of metho­
trexate (MTX) are administered [36-44], Lympho­
blasts, whose levels of TPMT activity correlate with 
the levels of activity found in RBC [20] are not 
available for investigation, because the patients are 
in remission during MT. Several studies performed 
with 6MP during MT suggested that the formation of 
TGN is mainly responsible for the treatment-out- 
come and for the drug toxicity [36-42]. This is 
supported by a significant positive correlation be­
tween high TGN levels in RBC and thiopurine 
induced bone marrow toxicity [41] and by negative 
correlations between TGN concentrations and TPMT 
activity [39] or between TGN concentrations and the 
incidence of relapse [39,40,42], MetIMP levels were 
not measured in the latter studies. Another study 
with RBC showed that MetIMP and TGN con­
centrations, as well as levels of TPMT activity, were 
below the population median in six out of the seven 
patients who relapsed [43], This raises the question 
whether low levels of TGN alone, or in combination 
with low MetIMP levels, in RBC during MT are 
responsible for the worse prognosis.
Evidence exists that the méthylation of 6MP, 
catalyzed by TPMT, modulates 6MP cytotoxicity 
and that the production of TGN alone is not suffi­
cient to explain the cytotoxic action of 6MP in vivo. 
TPMT-deficient patients, in whom methylated me­
tabolites could not be detected in RBC, did not suffer 
from toxicity after the dose of 6MP was reduced
considerably, but still had elevated TGN lev 
RBC compared to patients with unimpaired 1 
activity [36,38]. The tolerance of higher TGN 
centrations, without bone marrow depression, 
TPMT-deficient patients suggests that the meth; 
metabolites of 6MP also contribute to cytoto; 
This is also illustrated by the preliminary result 
recent study that showed identical effects on 
marrow toxicity, in patients who were treated 
either 6MP or 6-thioguaninc. However, the 
concentrations found in patients treated with 
were five times lower than those found in pi 
treated with 6-thioguanine [44|, So, in addition 
formation of TGN, the methylated metabolil 
6MP intracellularly may also contribute to 
marrow toxicity in vivo.
It is important to further elucidate whether 
ylation of thiopurines contributes to the cyt< 
action of 6MP in vivo, becausc this may 
clinical implications for the administration of 61 
6-thioguanine, which is converted directly into 
If methylation of 6MP only results in detoxifi 
of the drug, it would be better to adniinis 
thioguanine instead of 6MP, especially in pi 
with high TPMT activity. If the formati< 
MetIMP adds to the cytotoxic action of 6MP, \ 
TPMT activity would enhance the therapeutic 
of 6MP in the lymphoblasts. The cytotoxicity c 
by inhibition of the de novo synthesis of the 
would be lost if 6-thioguanine was admini 
instead of 6MP, because MetGMP is a twelv 
less potent inhibitor of the de novo synthesis 
purine than MetIMP [45].
4. Induction of TPMT activity
The levels of TPMT activity in RBC during ’ 
childhood ALL were higher compared to th 
diagnosis [20] and those of healthy controls 
TPMT activities showed low intra-patient vari 
(13.5%) during MT and were not influenc 
high-dose MTX infusions [20|. After cessât] 
MT the elevated levels of TPMT activity in 
decreased to normal levels 120,391. The first 
of another study showed that the levels of '
activity in RBC were elevated at the end 
intensive induction and consolidation treatmer
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just before the start of MT, and that they decreased 
during MT compared to the levels observed just 
before the start of the MT [46]. These observations 
suggest that induction of the TPMT activity in RBC 
occurs during the induction, consolidation or MT of 
childhood ALL [20,39,46]. It is not known whether 
the induction of TPMT activity also occurs in other 
tissues or in lymphoblasts, but the latter would be 
difficult to investigate because no lymphoblasts are 
available as soon as the patient is in remission. The 
biochemical mechanism for the induction of TPMT 
activity is not known,
High-dose 6MP infusions are currently being 
investigated in the induction and consolidation treat­
ment of childhood ALL |47|. Since melhylation of 
6MP and its metabolites occurs to a large extent, 
especially during high-dose 6MP infusions 
136,48,49] and, since 6MP infusions are administered 
over several courses [471, it is important Uv investi­
gate the influence of high-dose 6MP infusions on the 
TPMT activity. In order to evaluate the conse-
pMNC during treatment with high-dose 6MP infu­
sions.
quences of TPMT induction on the therapeutic effect 
of 6MP, it is essential to elucidate the contribution of 
the méthylation pathway to 6MP cytotoxicity, or 
detoxification, in vivo.
4.1. Effects of high-dose 6MP infusions on the 
activity of TPMT (pilot study)
A pilot study was performed to investigate the 
effect of high-dose 6MP infusions on the activity of 
TPMT and to explore the relationship between this 
activity and (methyl)thiopurine nucleotide levels. In 
the consolidation treatment using high-dose MTX 
infusions, of the Dutch Childhood Leukemia Study 
Group (ALL 8 study), patients with ALL were 
randomly divided into two groups; the first group 
were given high-dose 6MP intravenously and the 
second group received low-dose 6MR The group that 
were given low-dose 6MP orally were treated as the 
control group for the high-dose 6MP group, because 
both groups received MTX infusions which may 
influence TPMT levels as well. We analyzed 
peripheral blood mononuclear cells (pMNC), instead 
of RBC, because the patients frequently received 
RBC transfusions for anemia. This pilot study was 
the first study in ALL which investigated both the 
activity of TPMT and the metabolism of 6MP in
4.2 . Experimental
Twenty children (aged between 2 and 9 years) 
with medium-risk ALL were treated in our center. 
After induction of bone marrow remission, all pa­
tients received the M-protocol, a consolidation treat­
ment which consisted of four courses of treatment 
with high-dose MTX infusions (5 g /m 2 over 24 h) 
over 8 weeks. In addition, eleven of these patients 
were randomly selected for intravenous administra­
tion of 6MP (1300 m g/m 2 over 24 h given immedi­
ately after the MTX infusion i.e., from 24 to 48 h). 
The other nine patients received 6MP orally (25 
m g /n r daily over 8 weeks). Patients or parental 
approval were obtained according to the guidelines 
of the ethical committee of our hospital.
pMNC were isolated from 20 ml of deiibrinatcd 
blood by densily-gradient centrifugation and con­
taminating RBC were removed by a NH.,0 shock 
[50|. pMNC were isolated for measurement of 
TPMT activity before, and 2 weeks after, the M 
protocol. TPMT activity was measured according to 
the method of Van Loon and Weinshilboum [21], 
which is based on the méthylation of 6MP with
è A f
S-adenosyl-f.-[ ‘ C|-methionine. In short, 5*10’ 
pMNC were incubated with a solution consisting of 
potassium phosphate buffer, pH 7, 6MP in di- 
methylsulfoxide, S-adenosyI-i,-[ MC|-methionine, re­
duced glutathione and allopurinol. The incubation
was performed in a shaking water bath at 37 C for 
90 min after which time the reaction was terminated 
using borate buffer, pH I(),| MC]-MeMP was ex­
tracted from the reaction mixture using 20% isoamyl 
alcohol in toluene. Radioactivity was measured for 
10 min in a liquid scintillation counter and corrected 
for 3 separate blanks as described [21].
During the four courses of treatment, pMNC were 
isolated before and 24, 28, 48, 52 and 72 h after the 
start of each MTX infusion from eight patients 
treated intravenously and four patients treated orally. 
The (methyl)thiopurines were extracted, from pMNC 
(on ice), using perchloric acid and the pH was 
adjusted to between 6 and 7 with dipotassium 
hydrogen phosphate. The (methyl )thiopurine nucleo­
tides were separated by anion-exchange HPLC
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(Partisil-10-SAX, 250 X 4.6 mm I.D., particle size 
10 jx m, Whatman, Clifton, NJ, USA) and measured 
the UV absorbance was measured at 290 nra for 
MetIMP and at 320 nm for thiopurine nucleotides as 
described [50].
4.3. Results and discussion
The activity of TPMT in pMNC was measured 
before and after the M protocol (Table 1). Before the 
start of the M protocol the levels of activity of 
TPMT (range 4.6-27.2 IU/109 pMNC, mean 13.7) 
were in, or above, the range found in the lympho­
cytes of healthy adults (range 4.8-17.7 IU/109, 
mean 11.0) [21]. The higher levels of TPMT activity 
found might be caused by other chemotherapeutic 
drugs used during the induction treatment [20,39,46]. 
There was neither a statistically significant difference
Table 1
TPMT activity in pMNC (IU/10y pMNC) before and after the 
start of the M protocol
Patients TPMT activity before TPMT activity after 
M protocol protocol
Intravenous group
1 12.9 n.e.
2 14.4 7.6
3 n.d. 1 0 . 6
4 17.8 n.e.
5 22.5 29,4
6 7.8 n.e.
7 27.2 n.e.
8 15.7 n.d.
9 4.6 n.d.
1 0 9.7 3.5
li 7.8 4.1
Mean (S.E.M.) 11.0 (4.8)
Oral group
1 20.3 7,2
2 n,e. 2 2 . 6
3 17.2 28.9
4 7.3 7,0
5 n.e. 4.7
6 n.e. 16.Î
7 n.e. 7,3
8 7.1 n.e.
9 n.d. 6 . 2
Mean (S.E.M.) 12.5 (3.2)
Both groups
Range 4.6-27.2 3.5-29.4
Mean (S.E.M.) 13.7 (1.8) 11.9 (2.6)
n.d.—not done; n.e.-not enough,
between the levels of TPMT activity found 
before, or after, the M protocol in either < 
groups (paired t test /?=0.50 in the intravenoi 
p —0.94 in the oral group) nor in the TPMT ' 
obtained after the M protocol between th< 
groups (Mann-Whitney-Wilcoxon rank sum le
0.77).
The necessary 5*10° pMNC for the TPMT 
could not be obtained in 9 out of 36 cases, be 
several patients were leukopenic. For future re: 
in ALL, an assay for the TPMT activity, 
requires less pMNC will be needed. We re 
reported a non-radiochemical HPLC procedu 
other purine enzymes using 1500-15 000 \ 
[51], but we still have not been able to dev< 
sensitive HPLC assay for measuring TPMT a 
that requires less than 5*10° pMNC. Immunol 
techniques to detect the TPMT protein may 
sensitive alternative to the measurement of a 
[22]. However, more insight into the genetic 
for TPMT deficiency in the population is re 
before this technique can be used reliably.
In the group treated intravenously, MetIMP 
(Table 2) were measurable at the end of the 
infusion (48 h) and either increased or rer 
constant after termination of the infusion Iron) 
h. Patient 3 did not produce any MetIMP duri 
courses of treatment although his TPMT activi 
10,6 IU/109 pMNC after the M protocol. The 
patients produced significantly more MetIMP 
Course 4, compared to Course I (paired / te 
0,004, eleven patients). During the succ 
courses of treatment, patients 5 and 7 pr< 
MetIMP earlier (i.e., at 48 h instead of 52 ot 
than they did during the first course of tre¿ 
During Course 4, patient 5 produced Metí) 
early as 4 h after the start of the 6MP infusic 
pmol/106 pMNC at 28 h). in the group irea 
oral administration, MetIMP levels could i 
detected. Thiopurine nucleotides were not det< 
in both groups [detection limits are 13 and 3fc! 
for MetIMP and tGMP respectively, per injec 
100 /¿I (50)].
In the group treated intravenously, there \ 
correlation between the levels of TPMT i 
before the start of the M protocol and the IV 
levels after 72 h of the first course of treatm 
between the levels of 7"PMT activity after 
protocol and MetIMP levels during the fourth
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Table 2
MetIMP levels in pMNC (pmol/l()0) over four courses of treatment from patients treated with HD-MTX followed by HD-6 MP infusions .
Patient TPMT MetIMP
Before After Course 1 
(72h)
Course 2 
<72h)
Course 3
(72h)
Course 4 
(72h)
1 12.9 n.d." 13.3 14.6 21.9 18.4
2 14.4 7.6 2 1 , 2 29.3 52.7 48.0
3 n.d. 1 0 .fi 0 . 0 0 . 0 0 . 0 n.d.
4 17.8 n.d. 15.2 n.d, 17.2 30.4
5 22.5 29.4 7.2 14.4 29.1 18.5
7 ^ ( 4M n.d. 2 0 . 0 8 . 8 13.3 17.8
1 0 9,7 3.5 n.d n.d. 38,5 47.7
11 7.8 4.1 0 . 0 14.9 % • A* 4 A* 24.7
Mean 8.5 13.7 25.6 29.4
(S.R.M.) (3.1) (3.9) (5,7) (5.1)
Paired t test {/>) 0.035 0.023 0.004
compared to Course I
Levels Found 24 h after termination of the 6 MP infusion (72 h) are indicated. TPMT activities {IU/IO '1 pMNC) before and after the M 
protocol are also indicateti.
“n.d. • not done.
of treatment (Spearman’s correlation coefficients 
0.029 and -0.400, respectively). However, a larger 
number of patients would have to take part in the 
study before a conclusion could be drawn.
The significant increase in the levels of MetIMP in 
each patient during the successive courses of treat­
ment with high-dose 6MP and the acceleration of 
MetIMP formation during the infusions over succes­
sive courses of treatment, in patients 5 and 7, suggest 
that there might be induction of TPMT activity by 
high-dose 6MP. This observation needs to be con­
firmed by measuring the levels of TPMT activity in 
more patients, because higher MetIMP levels could 
also be caused by other enzymes, which are involved 
in the metabolism of 6MP (Fig. I). HGPRT activity 
in RBC was significantly higher in children during 
MT for leukemia compared to healthy control chil­
dren [52]. An induction of HGPRT during chemo­
therapy might be another explanation for the increas­
ing MetIMP levels in our study (Table 2), but 
HGPRT activity has never been investigated during 
high-dose 6MP infusions. Xanthine oxidase activity 
has not been studied with respect to the metabolism 
of high-dose 6MP. We described three patients who 
developed severe leukopenia due to thiopurine 
therapy for rheumatoid arthritis and who had very 
low levels of 5 'nucleotidase activity in pMNC |53|. 
So far, it has been clearly demonstrated in the 
literature that the levels of TPMT activity have a
major influence on the metabolism of 6MP, but other 
purine enzymes, which have been less well studied, 
may also interfere with the metabolism of 6MP.
'Phis pilot study is the first which measured TPMT 
activity in pMNC during the consolidation treatment 
of ALL and it demonstrated an increase in the levels 
of MetIMP in pMNC during successive courses of 
treatment with high-dose 6MP. This pilot study also 
showed the limitations involved when using pMNC: 
a high percentage of TPMT assays failed due to 
leukopenia in the patients. Since leukopenia often 
occurs and RBC transfusions are frequently required 
during the consolidation treatment, the influence of 
high-dose 6MP infusions on TPMT activity can only 
be investigated further when a TPMT assay that 
requires less pMNC has been developed.
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